Abbott Laboratories (ABT) Stock Overview
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
ABT Community Fair Values
Create NarrativeSee what 233 others think this stock is worth. Follow their fair value or set your own to get alerts.
Abbott Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$109.41 |
| 52 Week High | US$141.23 |
| 52 Week Low | US$105.27 |
| Beta | 0.72 |
| 1 Month Change | -11.90% |
| 3 Month Change | -13.03% |
| 1 Year Change | -14.82% |
| 3 Year Change | -1.21% |
| 5 Year Change | -12.12% |
| Change since IPO | 29,776.22% |
Recent News & Updates
Recent updates
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
Feb 02Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)
Jan 03
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem
Nov 05There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings
Sep 15Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
Apr 16Abbott Laboratories Basking In A Sharp Turn In Sentiment
Mar 16Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings
Feb 28
Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price
Feb 17Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?
Feb 05Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Jan 23Abbott Laboratories Q4 2024 Earnings Preview
Jan 08Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
Dec 21Abbott Laboratories: Investors Should Wait For A Pullback
Nov 25Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11Shareholder Returns
| ABT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.6% | -1.3% | -0.3% |
| 1Y | -14.8% | -7.7% | 14.5% |
Return vs Industry: ABT underperformed the US Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: ABT underperformed the US Market which returned 14.5% over the past year.
Price Volatility
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 3.9% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ABT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1888 | 114,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
| ABT fundamental statistics | |
|---|---|
| Market cap | US$190.05b |
| Earnings (TTM) | US$6.52b |
| Revenue (TTM) | US$44.33b |
Is ABT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABT income statement (TTM) | |
|---|---|
| Revenue | US$44.33b |
| Cost of Revenue | US$19.19b |
| Gross Profit | US$25.14b |
| Other Expenses | US$18.62b |
| Earnings | US$6.52b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.75 |
| Gross Margin | 56.71% |
| Net Profit Margin | 14.72% |
| Debt/Equity Ratio | 25.3% |
How did ABT perform over the long term?
See historical performance and comparisonDividends
Does ABT pay a reliable dividends?
See ABT dividend history and benchmarks| Abbott Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Jan 15 2026 |
| Dividend Pay Date | Feb 13 2026 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 10 days |
Does ABT pay a reliable dividends?
See ABT dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 09:06 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbott Laboratories is covered by 52 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |